Ankur Dave, DO
Infectious Disease · Palos Heights, ILNPI 1225327919
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 76.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $740 and has fallen 95.4% since, to $34 in 2025.
Across 92 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Relievant Medsystems, Inc.$122
- Vertiflex, Inc.$121
- Merck$48
- AbbVie$34
- Melinta Therapeutics, LLC$14
Across 26 payments — averaging $1300.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$34K
What the payments were for
- Travel & lodging$1218%
- Food & beverage$1,34492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 83 | $1,126 |
| Relievant Medsystems, Inc. | 1 | $122 |
| Vertiflex, Inc. | 1 | $121 |
| Merck | 4 | $48 |
| AbbVie | 2 | $34 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$244
- GENERAL PAIN MANAGEMENT$227
- GENERAL - THERAPIES$162
- Superion ISS$121
How this compares
$1,465 in reported general payments places this provider in the 75th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 47 | $194,756 |
| CeftriaxoneCeftriaxone Sodium | 11 | $4,104 |
| Vancomycin Hcl | 20 | $1,996 |
| Cefdinir | 42 | $1,255 |
| Cephalexin | 54 | $1,220 |
| Azithromycin | 26 | $889 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 59 | $770 |
| Ciprofloxacin Hcl | 30 | $347 |
| Doxycycline Hyclate | 21 | $338 |
| Metronidazole | 17 | $183 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $180 |
| Fluconazole | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Palos Heights
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
- James SullivanChicago$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.